Update on HER2 expression in breast cancer

Recent studies since the 2018 ASCO/CAP guideline update for HER2 testing in breast cancer have made novel discoveries in HER2-targeted therapy. These studies have elucidated a new subtype of breast cancer known as "HER2-low" breast cancers, which represents a distinct subgroup under what has been classified as HER2-negative breast cancer. Additionally, there is further understanding of alterations within the ERBB2 gene, including mutations in the tyrosine kinase domain, both de novo or as a resistance mechanism.
Source: Diagnostic Histopathology - Category: Pathology Authors: Tags: Mini-symposium: Breast pathology Source Type: research